Humoral and cellular immunogenicity two months after SARS-CoV-2 messenger RNA vaccines in patients with cancer
Authors:
Open Access
- 24 December 2021
- Vol. 25 (1) , 103699
Abstract
No abstract availableKeywords
Funding Information
- Merck Sharp and Dohme United Kingdom
- Pfizer
- Biomedical Advanced Research and Development Authority
- AstraZeneca
- Astellas Pharma
- Bristol-Myers Squibb
- Hôpitaux Universitaires de Genève
- Eli Lilly and Company
- Roche
This publication has 8 references indexed in Scilit:
- Serologic Status and Toxic Effects of the SARS-CoV-2 BNT162b2 Vaccine in Patients Undergoing Treatment for CancerJAMA Oncology, 2021
- Decreased infectivity following BNT162b2 vaccination: A prospective cohort study in IsraelThe Lancet Regional Health - Europe, 2021
- Immunogenicity of SARS-CoV-2 messenger RNA vaccines in patients with cancerCancer Cell, 2021
- Seroconversion rates following COVID-19 vaccination among patients with cancerCancer Cell, 2021
- Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UKThe Lancet, 2021
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 VaccineNew England Journal of Medicine, 2020
- Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19Cell, 2020
- Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed IndividualsCell, 2020